Damora Therapeutics, Inc. (DMRA)
Pharmaceutical Preparations
Latest Price
$24.75
TTM P/E
3.30
Normalized P/E
--
Div Yield
--
Book Value
10.88
P/B Ratio
2.28
Valuation metrics
adjust assumptions →EPS: $3.98
Book value / share: $150.49
Formula: √(22.5 × EPS × BVPS)
Graham Number
$116.09
+369% upside
EPS: $3.98
Target P/E: 3×
Formula: EPS × P/E
P/E Fair Value
$11.94
52% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 9.23M | $240.0M | 14.96% | +187.5K | 2026-06-30 |
| Fairmount Funds Management LLC | 8.71M | $226.0M | 14.11% | -- | 2026-06-30 |
| Avoro Capital Advisors LLC | 3.78M | $98.0M | 6.13% | -- | 2026-06-30 |
| Venrock Adviser, LLC | 3.60M | $93.0M | 5.84% | -- | 2026-06-30 |
| BlackRock, Inc. | 3.16M | $82.0M | 5.12% | +2.94M | 2026-06-30 |
| FCPM III SERVICES B.V. | 2.44M | $63.0M | 3.95% | -- | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 2.40M | $62.0M | 3.89% | +392 | 2026-06-30 |
| VIKING GLOBAL INVESTORS LP | 2.31M | $60.0M | 3.74% | -- | 2026-06-30 |
| Jupiter Topco LLC | 2.28M | $59.0M | 3.70% | -- | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.06M | $49.0M | 3.34% | -- | 2026-06-30 |